What type of study is this?

September 5, 2025Open Access

Covalent Inhibition of the Human Papillomavirus Type 16 E6 Protein Restores p53 and Suppresses HPV-Driven Tumorigenesis

View Full Paper

Ask AI

Bookmark

Authors

Covalent inhibitors restore p53 levels in HPV-infected cells, suggesting a novel strategy for HPV-related cancers.

Covalent inhibition of E6 protein restores p53 levels, leading to reduced tumor viability in HPV16-positive cells.
Inhibitors demonstrated a significant increase in p53 protein levels, activating pathways linked to apoptosis and senescence.
In vivo testing showed that E6 inhibition significantly suppresses tumor growth in HPV16 expressing cervical cancer models.
Targeting viral oncoproteins with covalent inhibitors may offer a promising therapeutic approach for HPV-associated malignancies.

Rietz et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark